← Leaderboards
Fernando Arias-Mendoza
Columbia University Health Sciences
$1,786,233
Attributed
$1,995,147
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,995,147 · 3
By mechanism
R01$1,222,597 · 1
R21$772,550 · 2
Top collaborators
- Kavindra Nath2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Laura Pasqualucci$5,549,983
- Scott A Small$25,024,830
- Tal Nuriel$6,961,826
- Eric C Greene$16,539,943
- Andrea Califano$71,130,512
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaProgramsTumorResponseMalignant NeoplasmsMetabolicFundingTreatment ResponseB-LymphocytesMagnetic FieldImaging ModalityCohortCancer PatientBasePhosphoethanolaminePhosphorylcholineNon-Hodgkin&AposMetabolismMethodologyPharmaceutical PreparationsMagnetic Resonance SpectroscopyLarge Cell Diffuse Non-Hodgkin&AposLymphomaMeasurement
Grant awards (5)
Translation of Noninvasive Metabolic Biomarkers to Targeted Therapy for Cancer$227,906
R21 · FY2025 · CA
Translation of Noninvasive Metabolic Biomarkers to Targeted Therapy for Cancer$189,922
R21 · FY2024 · CA
PREDICTING OUTCOME OF EXPERIMENTAL THERAPY IN LYMPHOMAS BY 31P & 1H MRS$169,836
R21 · FY2011 · CA · contact PI
IN VIVO 31P MRS STUDIES OF NON-HODGKIN'S LYMPHOMA$1,222,597
R01 · FY2010 · CA · contact PI
PREDICTING OUTCOME OF EXPERIMENTAL THERAPY IN LYMPHOMAS BY 31P & 1H MRS$184,886
R21 · FY2010 · CA · contact PI